{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wu BR"],"funding":["Taiwan Ministry of Health and Welfare Clinical Trial Center","Tseng-Lien Lin Foundation,","MOST Clinical Trial Consortium for Stroke"],"pagination":["5626"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9571401"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(19)"],"pubmed_abstract":["Statins exert cholesterol-independent beneficial effects, including immunomodulatory effects. In this study, we attempted to investigate the association between statin therapy and the risk of viral infection. We conducted a retrospective cohort study using data from Taiwan's National Health Insurance Research Database. We identified patients with hyperlipidemia and divided them into two cohorts: statin users and statin nonusers. A 1:1 propensity score matching was conducted between the two cohorts, and a Cox proportional hazards model was used to evaluate the risk of viral infection. Overall, a total of 20,202 patients were included in each cohort. The median follow-up durations were 4.41 and 6.90 years for statin nonusers and users, respectively. The risk of viral infection was 0.40-fold "],"journal":["Journal of clinical medicine"],"pubmed_title":["Statin Therapy and the Risk of Viral Infection: A Retrospective Population-Based Cohort Study."],"pmcid":["PMC9571401"],"funding_grant_id":["MOST 109-2321-B-039-002","MOHW109-TDU-B-212-114004","Taichung, Taiwan"],"pubmed_authors":["Liao WC","Yin MC","Chou CH","Lin CL","Peng YH","Ho WC","Wu BR","Chen DH"],"additional_accession":[]},"is_claimable":false,"name":"Statin Therapy and the Risk of Viral Infection: A Retrospective Population-Based Cohort Study.","description":"Statins exert cholesterol-independent beneficial effects, including immunomodulatory effects. In this study, we attempted to investigate the association between statin therapy and the risk of viral infection. We conducted a retrospective cohort study using data from Taiwan's National Health Insurance Research Database. We identified patients with hyperlipidemia and divided them into two cohorts: statin users and statin nonusers. A 1:1 propensity score matching was conducted between the two cohorts, and a Cox proportional hazards model was used to evaluate the risk of viral infection. Overall, a total of 20,202 patients were included in each cohort. The median follow-up durations were 4.41 and 6.90 years for statin nonusers and users, respectively. The risk of viral infection was 0.40-fold ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-05-29T21:27:24.79Z","creation":"2025-05-29T21:27:24.79Z"},"accession":"S-EPMC9571401","cross_references":{"pubmed":["36233493"],"doi":["10.3390/jcm11195626"]}}